

**budesonide 200mcg (Novolizer®) inhaler No. (306/06)**  
**Meda Pharmaceuticals Ltd**

**Product Update**

4 August 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

budesonide (Novolizer®) inhaler is accepted for use within NHS Scotland for the treatment of persistent asthma in adults and children over 6 years of age.

Budesonide (Novolizer®) inhaler offers an alternative to existing dry powder inhaled formulations of budesonide at a similar cost.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 12 June 2006.*

**Chairman,  
Scottish Medicines Consortium**